A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM

Summary

This is an open-label, single arm study to access the effect of treatment with D-VRD in patients with newly diagnosed standard risk multiple myeloma.

Timeline

Start

2021-12-01

Primary completion

2023-05-30

Completion

2024-12-31

Drugs

Indications